Methods for treating cognitive impairment in humans with Multiple Sclerosis

• US 7,619,005 B2
• Filed: 05/19/2005
• Issued: 11/17/2009
• Est. Priority Date: 11/01/2000
• Status: Expired due to Fees

• Current Assignee: Katherine Priestley
• Original Assignee: Cognition Pharmaceuticals LLC
• Inventors: Epstein, Mel H., Wiig, Kjesten A., Carpenter, Randall L.
• Primary Examiner(s): KWON, YONG SOK
• Application Number:
  US11/133,144
• Publication Number:
  US 20060111448A1
• Time in Patent Office: 1,643 Days
• Field of Search: None
• US Class Current: 514/654
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate

Abstract

Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.

Claims

1. A method of treating a human for an impairment in a cognitive function, comprising the step of administering an effective amount of an amphetamine composition that includes at least one member selected from the group consisting of l-amphetamine and l-methamphetamine to a human having an impairment in a cognitive function associated with multiple sclerosis, wherein the l-amphetamine is at least 60 mole percent l-amphetamine relative to the total l-amphetamine and l-methamphetamine components of the composition or wherein the l-methamphetamine is at least 90 mole percent l-methamphetamine relative to the total l-methamphetamine and l-amphetamine components of the composition.

2. The method of claim 1, wherein l-amphetamine is administered, and wherein the l-amphetamine is administered as a component of a composition that includes at least 80 mole percent l-amphetamine relative to the total l-amphetamine and l-methamphetamine components of the composition.

3. The method of claim 1, wherein l-methamphetamine is administered, and wherein the l-methamphetamine is administered as a component of a composition that includes at least 95 mole percent l-methamphetamine relative to the total l-methamphetamine and l-amphetamine components of the composition.

4. The method of claim 1, wherein at least one member selected from the group consisting of attention, executive function, reaction time, learning, information processing, conceptualization, problem solving and verbal fluency is improved in the human following administration of the amphetamine.

5. The method of claim 1, wherein the l-amphetamine is administered at a dose of about a 1 mg dose to about a 150 mg dose per day.

6. The method of claim 1, wherein the l-methamphetamine is administered at a dose of about a 1 mg dose to about a 150 mg dose per day.

7. The method of claim 2, wherein l-amphetamine is administered, and wherein the l-amphetamine is administered as a component of a composition that includes at least 99 mole percent l-amphetamine relative to the total l-amphetamine and l-methamphetamine components of the composition.

8. The method of claim 3, wherein l-methamphetamine is administered, and wherein the l-methamphetamine is administered as a component of a composition that includes at least 99 mole percent l-methamphetamine relative to the total l-methamphetamine and l-amphetamine components of the composition.